Let's be realistic here. The company's philosophy is to acquire new technology and license it. When the Flynn acquisition was announced the plan was to partner with big pharma or healthcare company or companies for big buck licensing agreements to the benefit of shareholder value. So far there have been no takers. Would anyone argue that if MSI proved any generation of the machine worked lucrative licensing deals would not have been done? Even generation 1 with 1000 times better than mammogram and zero false readings would be a huge lifesaver and healthcare dollar saver and would have seen partners lined up IF it was proven to work.
You don't have to be an insider to understand the problem here, the market defines it every day. The stock price reflects the CRS deal, and no value at all for anything else. So we wait for a machine that performs to a level that will be accepted by MDA for testing and hopefully the long-awaited proof that it works.